MarketPeel
Insider Trading Intelligence
KS

Karen Sims

ABUS
CHIEF MEDICAL OFFICER · ARBUTUS BIOPHARMA CORP · CIK 0001984652
FILING MIX · LIFETIME67%/33%
BUYS
4
SELLS
2
TOTAL VALUE
$73.6K
COMPANIES
1
ACTIVE SINCE
Feb 2024
HOLDINGS NOW
155,494
AVG SELL PX
$3.10
TRADE KIND
SHOWING 6 / 6
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Karen Sims, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+50.00%+7.24%+0.99%+6.25%+6.25%
14d2+0.00%+10.92%+1.33%+9.60%+9.60%
30d2+0.00%+7.08%-0.60%+7.68%+7.68%
60d2+50.00%+1.01%-5.25%+6.26%+6.26%
90d2+0.00%+8.54%-1.80%+10.34%+10.34%
180d2+50.00%+28.90%+8.66%+20.24%+20.24%
1y2+0.00%+27.70%+18.84%+8.86%+8.86%
2y2(1 pending)+0.00%+84.45%+42.90%+41.55%+41.55%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ABUS · 155,494 shares · as of Feb 14, 2025
0100,975201,950302,925403,9002025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2024
2024
2025
FLOW · 4 buys / 2 sellsCOVERAGE · 5 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
200,300200,300Feb 14, 2025Feb 19, 2025View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
49,300155,494Feb 14, 2025Feb 19, 2025View →
ABUS
ARBUTUS BIOPHARMA CORP
SALE10b5-1
10b5-1 plan
19,348$3.28$63.5K106,194Feb 4, 2025Feb 5, 2025View →
ABUS
ARBUTUS BIOPHARMA CORP
SALE10b5-1
10b5-1 plan
4,358$2.31$10.1K125,542Feb 2, 2024Feb 5, 2024View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
403,900403,900Feb 1, 2024Feb 5, 2024View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
101,000129,900Feb 1, 2024Feb 5, 2024View →
Other insiders · ABUS
Loading peer insiders…
About this filer
CIK 0001984652
ROLE
Chief Medical Officer
PRIMARY
ABUS
COMPANIES
1
ACTIVE SINCE
Feb 2024
MARKETPEEL · /INSIDER/0001984652DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback